Given that human leukemia patients with MLL-AF9 are resistant to chemotherapy [1, 11], our findings suggest that pharmacological inhibition of Necdin may hold potential as a novel therapy for leukemia patients with MLL translocations. Here, KMT2A is linked to leukemia.